Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

NCT06576102

CompletedN/A

Sponsor: Maddalena Giannella

Conditions: Persistent COVID-19, B Cell Malignancies

Interventions: Persisting SARS-CoV-2 infection

Countries: Italy, Spain

Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients with humoral immunity deficiency.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of B cell malignancies or previous treatment with B cell targeting therapies.
* Diagnosis of proven SARS-CoV-2 infection confirmed by a PCR test (only the first infection during the study period will be considered, re-infection will be counted as a secondary endpoint).
* Provision of signed and dated informed consent.

Exclusion Criteria:

* None
Locations (5)
  • Bologna, Bologna, Italy
  • Milan, Milan, Italy
  • Roma, Roma, Italy
  • Verona, Verona, Italy
  • Seville, Seville, Spain